A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer

NCT01872416 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DEVICE: Liposomal Doxorubicin Combined With ifosfamide

Sponsor

The First Affiliated Hospital of Guangzhou Medical University